Acute Coronary Syndrome, Arrhythmias, Cardiac, Atrial Fibrillation, Heart Failure
Conditions
Keywords
chronic heart failure, acute coronary syndrome, SGLT-2 inhibitors, anticoagulants, atrial fibrillation, NTproBNP, cardiac implanted electronic device, observationl
Brief summary
Cardiology Research Dubrava registry is a prospective, single centre registry including patients with acute coronary syndrome with and without ST segment elevation, patients with heart failure who were prescribed with SGLT-2 inhibitors, patients implanted with TAVI, patients with venous thromboembolism, patients with pulmonary embolism who underwent thromboaspiration procedure, patients implanted with ICD, CRT and conduction system pacing devices, as well as patients with atrial fibrillation who underwent pulmonary vein isolation and are prescribed with long-term anticoagulation therapy.
Detailed description
Cardiology Research Dubrava registry is a prospective, single centre registry including patients with acute coronary syndrome with and without ST segment elevation, patients with heart failure who were prescribed with SGLT-2 inhibitors, patients implanted with TAVI, patients with venous thromboembolism, patients with pulmonary embolism who underwent thromboaspiration procedure, patients implanted with ICD, CRT and conduction system pacing devices, as well as patients with atrial fibrillation who underwent pulmonary vein isolation and are prescribed with long-term anticoagulation therapy. In this long-term follow-up registry we plan to collect data on clinical status, standard laboratory results including lipidogram values, NTproBNP values after specific interventions (in.ex. TAVI implantation, SGLT2inh prescripition), bleeding complications, and every major cardiovascular event, including cardiovascular death and all cause death.
Interventions
OTHERSGLT-2 inh therapy, CIED implantation, thromboaspiration,
long-term follow up and observation of patients treated in Cardiology department in the tertiary center and University hospital
Sponsors
University Hospital Dubrava
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
patients implanted with CIED, or with VTE, or with ACS or with TAVI -
Exclusion criteria
non compliance, not undergoing follow-up at this center \-
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| cardiovascular death | 10 years | death due to cardiovascular etiology during long term follow-up |
| freedom from atrial arrhythmias | 10 years | Freedom from atrial arrhythmias after PVI during mid-term folow-up (1 year) and long-term follow-up |
| Time to revascularization | 10 years | Time to revascularization during acute coronary syndrome |
| Bleeding complications | 10 years | Bleeding complications during long-term follow-up in patients prescribed with oral anticoagulation and/or antithrombotic therapy |
| Laboratory levels of NTproBNP | 10 years | Laboratory levels of NTproBNP in patients with AFib after PVI, in patients with HF prescribed with SGLT2 inhibitors, in patients with ACS after complete revasculariazation, in patients implanted with CIED |
Countries
Croatia
Contacts
Primary ContactIvan Zeljkovic, M.D.
Backup ContactIvana Jurin, M.D.
Outcome results
None listed